These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 6304787)
1. Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease. Casacchia M; Meco G; Castellana F; Bedini L; Cusimano G; Agnoli A Pharmacol Res Commun; 1983 Mar; 15(3):329-34. PubMed ID: 6304787 [TBL] [Abstract][Full Text] [Related]
2. Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats. Sasaki H; Hashimoto K; Maeda Y; Inada T; Kitao Y; Fukui S; Iyo M Life Sci; 1995; 56(25):PL443-7. PubMed ID: 7791505 [TBL] [Abstract][Full Text] [Related]
3. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. Marcoz P; Prigent AF; Lagarde M; Nemoz G Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905 [TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects induced by rolipram, a selective cAMP phosphodiesterase inhibitor: interaction with adrenergic and calcium affecting drugs. Novara V; Flugy A; Antona A; Latteri S; Palazzoadriano M; Cannizzaro G Pharmacol Res; 1990; 22 Suppl 1():51-2. PubMed ID: 2178260 [No Abstract] [Full Text] [Related]
5. Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor. Barnard JW; Seibert AF; Prasad VR; Smart DA; Strada SJ; Taylor AE; Thompson WJ J Appl Physiol (1985); 1994 Aug; 77(2):774-81. PubMed ID: 8002527 [TBL] [Abstract][Full Text] [Related]
6. Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram. Iyo M; Bi Y; Hashimoto K; Inada T; Fukui S Eur J Pharmacol; 1996 Sep; 312(2):163-70. PubMed ID: 8894591 [TBL] [Abstract][Full Text] [Related]
7. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. Wachtel H J Pharm Pharmacol; 1983 Jul; 35(7):440-4. PubMed ID: 6136585 [TBL] [Abstract][Full Text] [Related]
8. Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons. Yamashita N; Hayashi A; Baba J; Sawa A Jpn J Pharmacol; 1997 Oct; 75(2):155-9. PubMed ID: 9414030 [TBL] [Abstract][Full Text] [Related]
9. Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol. Sasaki H; Hashimoto K; Inada T; Fukui S; Iyo M Eur J Pharmacol; 1995 Aug; 282(1-3):71-6. PubMed ID: 7498291 [TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of rolipram on partially purified phosphodiesterase 4 from rat brains. Ohsawa F; Yamauchi M; Nagaso H; Murakami S; Baba J; Sawa A Jpn J Pharmacol; 1998 Jun; 77(2):147-54. PubMed ID: 9681571 [TBL] [Abstract][Full Text] [Related]
11. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism. Zhu WH; Majluf-Cruz A; Omburo GA Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035 [TBL] [Abstract][Full Text] [Related]
12. Stimulation of beta adrenoceptors in a human monocyte cell line (U937) up-regulates cyclic AMP-specific phosphodiesterase activity. Torphy TJ; Zhou HL; Cieslinski LB J Pharmacol Exp Ther; 1992 Dec; 263(3):1195-205. PubMed ID: 1335058 [TBL] [Abstract][Full Text] [Related]
13. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. Wachtel H Neuropharmacology; 1983 Mar; 22(3):267-72. PubMed ID: 6302550 [TBL] [Abstract][Full Text] [Related]
14. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram. Kochetkova M; Burns FM; Souness JE Biochem Pharmacol; 1995 Dec; 50(12):2033-8. PubMed ID: 8849330 [TBL] [Abstract][Full Text] [Related]
15. Effects of rolipram on in vivo dopamine receptor binding. Hosoi R; Ishikawa M; Kobayashi K; Gee A; Yamaguchi M; Inoue O J Neural Transm (Vienna); 2002 Sep; 109(9):1139-49. PubMed ID: 12203041 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Souness JE; Hassall GA; Parrott DP Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. Marivet MC; Bourguignon JJ; Lugnier C; Mann A; Stoclet JC; Wermuth CG J Med Chem; 1989 Jul; 32(7):1450-7. PubMed ID: 2544722 [TBL] [Abstract][Full Text] [Related]
18. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4. Miotla JM; Teixeira MM; Hellewell PG Am J Respir Cell Mol Biol; 1998 Mar; 18(3):411-20. PubMed ID: 9490659 [TBL] [Abstract][Full Text] [Related]
19. Multifactorial regulation of pituitary adenylate cyclase-activating polypeptide (PACAP)-induced production of cyclic AMP in ATT-20 corticotrophs: major involvement of Rolipram-sensitive and insensitive phosphodiesterases. Koch B; Lutz-Bucher B Mol Cell Endocrinol; 1995 Jul; 112(1):27-34. PubMed ID: 7589782 [TBL] [Abstract][Full Text] [Related]
20. Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors. Griebel G; Misslin R; Vogel E; Bourguignon JJ Pharmacol Biochem Behav; 1991 Jun; 39(2):321-3. PubMed ID: 1658815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]